262 related articles for article (PubMed ID: 12490738)
1. A dose-escalation study of weekly topotecan, cisplatin, and gemcitabine front-line therapy in patients with inoperable non-small cell lung cancer.
Guarino MJ; Schneider CJ; Grubbs SS; Biggs DD; Himelstein AL; Hogaboom K; Tilak S
Oncologist; 2002; 7(6):509-15. PubMed ID: 12490738
[TBL] [Abstract][Full Text] [Related]
2. Combined therapy with topotecan and gemcitabine in patients with inoperable or metastatic non-small cell lung cancer.
Dabrow MB; Francesco MR; Gilman PB; Cantor R; Rose L; Meyer TJ
Cancer Invest; 2003; 21(4):517-25. PubMed ID: 14533441
[TBL] [Abstract][Full Text] [Related]
3. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
Voortman J; Smit EF; Honeywell R; Kuenen BC; Peters GJ; van de Velde H; Giaccone G
Clin Cancer Res; 2007 Jun; 13(12):3642-51. PubMed ID: 17575229
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II study of 3-week cycle cisplatin-gemcitabine in advanced non-small cell lung cancer.
Kusaba H; Tamura T; Shimoyama T; Hotta K; Inoue A; Nokihara H; Ueda Y; Akiyama Y; Yamamoto N; Sekine I; Kunitoh H; Ohe Y; Kodama T; Saijo N
Jpn J Clin Oncol; 2002 Feb; 32(2):43-7. PubMed ID: 11948227
[TBL] [Abstract][Full Text] [Related]
5. A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer.
Kontopodis E; Kotsakis A; Kentepozidis N; Syrigos K; Ziras N; Moutsos M; Filippa G; Mala A; Vamvakas L; Mavroudis D; Georgoulias V; Agelaki S
Cancer Chemother Pharmacol; 2016 May; 77(5):949-56. PubMed ID: 26994909
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group.
Frasci G; Panza N; Comella P; Nicolella GP; Natale M; Manzione L; Bilancia D; Cioffi R; Maiorino L; De Cataldis G; Belli M; Micillo E; Mascia V; Massidda B; Lorusso V; De Lena M; Carpagnano F; Contu A; Pusceddu G; Comella G
J Clin Oncol; 1999 Aug; 17(8):2316-25. PubMed ID: 10561293
[TBL] [Abstract][Full Text] [Related]
7. Prospective phase II trial of a combination of fixed dose rate infusion of gemcitabine with cisplatin and UFT as a first-line treatment in patients with advanced non-small-cell lung carcinoma.
Shin SJ; Kim H; Baek JH; Ahn JJ; Jegal Y; Seo KW; Park CR; Shin JK; Jung JP; Kim JW; Cha HJ; Kwon WJ; Jeong AK; Noh YJ; Park JH; Min YJ
Lung Cancer; 2008 Apr; 60(1):83-91. PubMed ID: 18006180
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV non-small-cell lung cancer.
Isokangas OP; Knuuttila A; Halme M; Mäntylä M; Lindström I; Nikkanen V; Viren M; Joensuu H; Mattson K
Ann Oncol; 1999 Sep; 10(9):1059-63. PubMed ID: 10572603
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
Kakolyris S; Papadakis E; Tsiafaki X; Kalofonos C; Rapti A; Toubis M; Bania E; Kouroussis C; Chainis K; Androulakis N; Agelaki S; Sarra E; Vardakis N; Georgoulias V;
Lung Cancer; 2001 May; 32(2):179-87. PubMed ID: 11325489
[TBL] [Abstract][Full Text] [Related]
10. Combination of gemcitabine and cisplatin for advanced non-small cell lung cancer: a phase II study with emphasis on scheduling.
Huisman C; Giaccone G; van Groeningen CJ; Sutedja G; Postmus PE; Smit EF
Lung Cancer; 2001; 33(2-3):267-75. PubMed ID: 11551422
[TBL] [Abstract][Full Text] [Related]
11. A new cisplatin/gemcitabine schedule in locally advanced (IIIB) and metastatic (IV) non-small cell lung cancer: relationship between dose-intensity and efficacy. A phase II study.
Rossi D; Graziano F; Catalano V; Giordani P; Fedeli SL; Alessandroni P; Fedeli A; Dennetta D; Ugolini M; Catalano G
Anticancer Res; 2002; 22(5):3087-92. PubMed ID: 12530048
[TBL] [Abstract][Full Text] [Related]
12. Weekly gemcitabine and monthly cisplatin for advanced non-small cell lung carcinoma.
Abratt RP; Hacking DJ; Goedhals L; Bezwoda WR
Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-18-S8-23. PubMed ID: 9207311
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma.
Gajra A; Mehdi SA; Kirshner J; Newman N; Graziano SL
Lung Cancer; 2001 May; 32(2):189-96. PubMed ID: 11325490
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma.
Raymond E; Burris HA; Rowinsky EK; Eckardt JR; Rodriguez G; Smith L; Weiss G; Von Hoff DD
Ann Oncol; 1997 Oct; 8(10):1003-8. PubMed ID: 9402174
[TBL] [Abstract][Full Text] [Related]
15. Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15.
Cortesi E; Ramponi S; Corona M; Moscetti L; Grifalchi F; Oliva A; Lembo A; Gasperoni S; Padovani A
Lung Cancer; 2001; 31(2-3):271-6. PubMed ID: 11165407
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine and cisplatin treatment of advanced-stage non-small-cell lung cancer in patients given cisplatin on day 8.
Akcali Z; Calikusu Z; Sakalli H; Ozyilkan O
Tumori; 2008; 94(4):474-80. PubMed ID: 18822681
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale.
Gebbia V; Galetta D; Caruso M; Verderame F; Pezzella G; Valdesi M; Borsellino N; Pandolfo G; Durini E; Rinaldi M; Loizzi M; Gebbia N; Valenza R; Tirrito ML; Varvara F; Colucci G;
Lung Cancer; 2003 Feb; 39(2):179-89. PubMed ID: 12581571
[TBL] [Abstract][Full Text] [Related]
18. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
Giaccone G; Herbst RS; Manegold C; Scagliotti G; Rosell R; Miller V; Natale RB; Schiller JH; Von Pawel J; Pluzanska A; Gatzemeier U; Grous J; Ochs JS; Averbuch SD; Wolf MK; Rennie P; Fandi A; Johnson DH
J Clin Oncol; 2004 Mar; 22(5):777-84. PubMed ID: 14990632
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer.
Jang J; Kim HK; Cho BC; Lee KH; Yun HJ; Woo IS; Song HS; Ryoo HM; Kim CH; Sun DS; Shin JW
Cancer Chemother Pharmacol; 2017 May; 79(5):873-880. PubMed ID: 28341958
[TBL] [Abstract][Full Text] [Related]
20. A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy.
Kakolyris SS; Kouroussis C; Koukourakis M; Kalbakis K; Mavroudis D; Vardakis N; Georgoulias V
Anticancer Res; 2002; 22(3):1891-6. PubMed ID: 12168889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
